Bone substitute enters orthopaedic trial:
This article was originally published in Clinica
ETEX, a biomaterials company based in Cambridge, Massachusetts, has begun a US clinical trial of its Alpha-BSM bone substitute material in non-diaphyseal tibia fractures. The product is already cleared in the US for dental, periodontal and craniofacial applications but approval for orthopaedic applications could open it up to a potential $465 million market. The trial will likely be completed by the beginning of next year, said ETEX.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.